Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study

Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention

“…We identified 11 studies that utilized dopamine agonists for the prevention of OHSS. Of these, eight studies evaluated dopamine agonists against placebo, no intervention or standard care: five of these used cabergoline 0.5 mg/day for 8 days and one used it for 21 days, one used bromocriptine 2.5 mg/day for 14 days, and one used quinagolide (50–200 µg/day) for 21 days. Two studies compared cabergoline 0.5 mg/day for 7–8 days with 20 g albumin on the day of oocyte retrieval, and one with coasting (see below).…”

Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline

“…To that end, there is a growing body of evidence evaluating the administration of dopamine agonist (cabergoline) to reduce the severity and incidence of OHSS. This includes eight randomized controlled studies (82)(83)(84)(85)(86)(87)(88)(89). A prospective, randomized, double-blind study assessed oocyte donors who were administered cabergoline 0.5 mg/day (n ¼ 37) or placebo (n ¼ 32) from the day of hCG for 8 days.…”

Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome

“…In addition, a VEGFA polymorphism has been as recently identified as a risk allele for OHSS [26]. VEGF-mediated VP is thought to act through KDR-dependent mechanisms and dopamine/dopamine receptor agonists [27,36], which purportedly inhibit KDR function, have shown promise as therapies for OHSS [27,39,42-44]. Interestingly, we observed a moderate association between the (rs2305948/rs1870378/rs2305945) C-T-G haplotype and lower OHSS risk.…”

“…In support of this, inhibition of both VEGF [34,35] and KDR [22,31,32,35] has been shown to ameliorate VP development in models of OHSS. In addition, dopamine [36] and [37] dopamine receptor agonists [20,27,38-40] are known inhibit KDR function [36,41] and show promise as both preventative and therapeutic options for OHSS [39,42-45]. …”